نتائج البحث - Jonathan Kay

تنقيح النتائج
  1. 1
    Biosimilars: a regulatory perspective from America

    Biosimilars: a regulatory perspective from America حسب Jonathan Kay

    منشور في 2011
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  2. 2
    Biosimilars to treat inflammatory arthritis: the challenge of proving identity

    Biosimilars to treat inflammatory arthritis: the challenge of proving identity حسب Jonathan Kay, Josef S Smolen

    منشور في 2013
    احصل على النص الكامل احصل على النص الكامل
    Carta
    أضف إلى المفضلة
    محفوظ في:
  3. 3
    Evolution of treatment for rheumatoid arthritis

    Evolution of treatment for rheumatoid arthritis حسب Katherine S. Upchurch, Jonathan Kay

    منشور في 2012
    احصل على النص الكامل
    Revisão
    أضف إلى المفضلة
    محفوظ في:
  4. 4
    Isolation and characterization of beta-glucan receptors on human mononuclear phagocytes.

    Isolation and characterization of beta-glucan receptors on human mononuclear phagocytes. حسب J K Czop, Jonathan Kay

    منشور في 1991
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  5. 5
    The role of interleukin-1 in the pathogenesis of rheumatoid arthritis

    The role of interleukin-1 in the pathogenesis of rheumatoid arthritis حسب Jonathan Kay, Leonard H. Calabrese

    منشور في 2004
    احصل على النص الكامل
    Revisão
    أضف إلى المفضلة
    محفوظ في:
  6. 6
    Bone Damage in Rheumatoid Arthritis: Mechanistic Insights and Approaches to Prevention

    Bone Damage in Rheumatoid Arthritis: Mechanistic Insights and Approaches to Prevention حسب Sougata Karmakar, Jonathan Kay, Ellen M. Gravallese

    منشور في 2010
    احصل على النص الكامل
    Revisão
    أضف إلى المفضلة
    محفوظ في:
  7. 7
    Epidural Triamcinolone Suppresses the Pituitary-Adrenal Axis in Human Subjects

    Epidural Triamcinolone Suppresses the Pituitary-Adrenal Axis in Human Subjects حسب Jonathan Kay, James W. Findling, Hershel Raff

    منشور في 1994
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  8. 8
    Biosimilars in rheumatology: what the clinician should know

    Biosimilars in rheumatology: what the clinician should know حسب Gilberto Castañeda‐Hernández, Rodrigo González‐Ramírez, Jonathan Kay, Morton Scheinberg

    منشور في 2015
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  9. 9
    Activation of CD4 cells by fibronectin and anti-CD3 antibody. A synergistic effect mediated by the VLA-5 fibronectin receptor complex.

    Activation of CD4 cells by fibronectin and anti-CD3 antibody. A synergistic effect mediated by the VLA-5 fibronectin receptor complex. حسب Tomohiko Matsuyama, Akira Yamada, Jonathan Kay, Kenneth M. Yamada, Shuji Akiyama, S F Schlossman, C Morimoto

    منشور في 1989
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  10. 10
    Health informatics competencies in postgraduate medical education and training in the UK: a mixed methods study

    Health informatics competencies in postgraduate medical education and training in the UK: a mixed methods study حسب Lydia Jidkov, Matthew Alexander, Pippa Bark, John G Williams, Jonathan Kay, Paul Taylor, Harry Hemingway, Amitava Banerjee

    منشور في 2019
    احصل على النص الكامل احصل على النص الكامل
    Revisão
    أضف إلى المفضلة
    محفوظ في:
  11. 11
    Golimumab 3-year safety update: an analysis of pooled data from the long-term extensions of randomised, double-blind, placebo-controlled trials conducted in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis

    Golimumab 3-year safety update: an analysis of pooled data from the long-term extensions of randomised, double-blind, placebo-controlled trials conducted in patients with rheumatoi... حسب Jonathan Kay, Roy Fleischmann, Edward Keystone, Elizabeth C. Hsia, Benjamin Hsu, M. Mack, Neil Goldstein, Jürgen Braun, Arthur Kavanaugh

    منشور في 2013
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  12. 12
    β2-microglobulin modified with advanced glycation end products modulates collagen synthesis by human fibroblasts

    β2-microglobulin modified with advanced glycation end products modulates collagen synthesis by human fibroblasts حسب William F. Owen, Fan Fan Hou, Robert O. Stuart, Jonathan Kay, Joshua A. Boyce, Glenn M. Chertow, Ann Marie Schmidt

    منشور في 1998
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  13. 13
    Clinical disease activity and acute phase reactant levels are discordant among patients with active rheumatoid arthritis: acute phase reactant levels contribute separately to predicting outcome at one year

    Clinical disease activity and acute phase reactant levels are discordant among patients with active rheumatoid arthritis: acute phase reactant levels contribute separately to predi... حسب Jonathan Kay, Olga Morgacheva, Susan Messing, Joel M. Kremer, Jeffrey D. Greenberg, George Reed, Ellen M. Gravallese, Daniel E. Furst

    منشور في 2014
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  14. 14
    Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial

    Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial حسب Gerd R Burmester, William F. C. Rigby, Ronald van Vollenhoven, Jonathan Kay, Andrea Rubbert‐Roth, Ariella Kelman, Sophie Dimonaco, Nina Mitchell

    منشور في 2015
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  15. 15
    Tocilizumab combination therapy or monotherapy or methotrexate monotherapy in methotrexate-naive patients with early rheumatoid arthritis: 2-year clinical and radiographic results from the randomised, placebo-controlled FUNCTION trial

    Tocilizumab combination therapy or monotherapy or methotrexate monotherapy in methotrexate-naive patients with early rheumatoid arthritis: 2-year clinical and radiographic results... حسب Gerd R Burmester, William F. C. Rigby, Ronald van Vollenhoven, Jonathan Kay, Andrea Rubbert‐Roth, Ricardo Blanco, Alysha Kadva, Sophie Dimonaco

    منشور في 2017
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  16. 16
    The changing landscape of biosimilars in rheumatology

    The changing landscape of biosimilars in rheumatology حسب Thomas Dörner, Vibeke Strand, Paul Cornes, João Gonçalves, László Gulàcsi, Jonathan Kay, Tore K Kvien, Josef S Smolen, Yoshiya Tanaka, Gerd R. Burmester

    منشور في 2016
    احصل على النص الكامل احصل على النص الكامل
    Revisão
    أضف إلى المفضلة
    محفوظ في:
  17. 17
    Golimumab in patients with active rheumatoid arthritis who have previous experience with tumour necrosis factor inhibitors: results of a long-term extension of the randomised, double-blind, placebo-controlled GO-AFTER study through week 160

    Golimumab in patients with active rheumatoid arthritis who have previous experience with tumour necrosis factor inhibitors: results of a long-term extension of the randomised, doub... حسب Josef S Smolen, Jonathan Kay, Robert Landewé, Eric L. Matteson, Norman Gaylis, J. Wollenhaupt, Frederick T. Murphy, Yiying Zhou, Elizabeth C. Hsia, Mittie K. Doyle

    منشور في 2012
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  18. 18
    Sarilumab for the treatment of ankylosing spondylitis: results of a Phase II, randomised, double-blind, placebo-controlled study (ALIGN)

    Sarilumab for the treatment of ankylosing spondylitis: results of a Phase II, randomised, double-blind, placebo-controlled study (ALIGN) حسب Joachim Sieper, Jürgen Braun, Jonathan Kay, Salvatore Badalamenti, Allen Radin, Lixia Jiao, Stefano Fiore, Tanya M. Momtahen, George D. Yancopoulos, Neil Stahl, Robert D. Inman

    منشور في 2014
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  19. 19
    Golimumab in patients with active rheumatoid arthritis after treatment with tumor necrosis factor α inhibitors: findings with up to five years of treatment in the multicenter, randomized, double-blind, placebo-controlled, phase 3 GO-AFTER study

    Golimumab in patients with active rheumatoid arthritis after treatment with tumor necrosis factor α inhibitors: findings with up to five years of treatment in the multicenter, rand... حسب Josef S Smolen, Jonathan Kay, Mittie K. Doyle, Robert Landewé, Eric L. Matteson, Norman Gaylis, J. Wollenhaupt, Frederick T. Murphy, Stephen Xu, Yiying Zhou, Elizabeth C. Hsia

    منشور في 2015
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  20. 20
    EARLIER TREATMENT OF NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS WITH CERTOLIZUMAB PEGOL RESULTS IN IMPROVED CLINICAL AND PATIENT-REPORTED OUTCOMES

    EARLIER TREATMENT OF NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS WITH CERTOLIZUMAB PEGOL RESULTS IN IMPROVED CLINICAL AND PATIENT-REPORTED OUTCOMES حسب Gustavo Gomes Resende, Jonathan Kay, Lianne S. Gensler, Atul Deodhar, Walter P. Maksymowych, Nigil Haroon, Simone E. Auteri, Natasha de Peyrecave, T. Kumke, Bengt Hoepken, Lars Bauer, Martín Rudwaleit

    منشور في 2021
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:

أدوات البحث: